Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPediatrics/NeonatologyAetna Neonatal Hyperbilirubinemia Coverage Update …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0332

    Neonatal Hyperbilirubinemia

    Customize your policy alerts

    Sign up for Aetna Policy 0332 alerts

    Get alerted when Policy 0332 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This Aetna clinical policy bulletin defines medical necessity criteria for assessment and treatment of neonatal hyperbilirubinemia (including phototherapy, exchange transfusion, G6PD testing, home phototherapy) and lists interventions considered experimental/investigational. It applies to neonatal/pediatric providers treating newborn jaundice.

    Policy Summary
    PayerAetna
    PolicyNeonatal Hyperbilirubinemia
    Policy CodePolicy 0332
    Change TypeNo material changes
    Effective DateMay 25, 1999
    Last ReviewAug 10, 2023
    Next Review DateMar 28, 2024
    Key ActionDocument eligibility and follow-up for home phototherapy: infant ≥35 weeks, feeding well, TSB within allowed range, and arrange evaluation within 48 hours.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Table-basedTSB thresholds
    35+ weeksHome phototherapy
    9 itemsExperimental interventions
    No benefitZinc evidence
    82+References
    08/10/2023Last review

    Medical Necessity and Coverage Criteria

    Primary medical necessity criteria

    Assessment and treatment considered medically necessary when the following criteria are met:

    Assessment: G6PD testing: Measure G6PD levels for jaundiced infants who are receiving phototherapy, have poor response to phototherapy, or are at increased risk of G6PD deficiency due to family history, ethnic or geographic origin.
    Treatment: Phototherapy for term and near-term infants: Phototherapy per American Academy of Pediatrics (AAP) guidelines using age-in-hours specific TSB thresholds adjusted for gestational age and presence/absence of risk factors (isoimmune hemolytic disease, G6PD deficiency, asphyxia, significant lethargy, temperature instability, sepsis, acidosis, or albumin <3.0 g/dL).See Table 1

    Prophylactic phototherapy is medically necessary for rapid rise in bilirubin (>1 mg/dL/hour) or as a temporary measure pending exchange transfusion.

    Treatment: Exchange transfusion:
    Policy Summary
    PayerAetna
    PolicyNeonatal Hyperbilirubinemia
    Policy CodePolicy 0332
    Change TypeNo material changes
    Effective DateMay 25, 1999
    Last ReviewAug 10, 2023
    Next Review DateMar 28, 2024
    Key ActionDocument eligibility and follow-up for home phototherapy: infant ≥35 weeks, feeding well, TSB within allowed range, and arrange evaluation within 48 hours.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaProcedure, Drug and Diagnosis CodesProvider Requirements, Prior Authorization and Operational GuidanceClinical Background and Evidence SummaryDefinitions and Risk FactorsPolicy Dates and Revision History
    Exchange transfusion for term and near-term infants according to AAP guidelines and age-in-hours specific TSB thresholds.
    See Table 2

    Home Phototherapy

    Home phototherapy is covered when ALL of the following criteria are met:

    Home phototherapy eligibility: Infant is otherwise ready for discharge; feeding well, active, and appears well; gestational age ≥35 weeks; TSB less than 20–22 mg/dL in term infants or less than 18 mg/dL in preterm infants; and arrangements are made for evaluation within 48 hours by early clinic visit or trained home health nurse who can perform follow-up assessments and blood draws, clinically assess jaundice, set up and oversee phototherapy equipment, encourage frequent feedings, and weigh the infant.TSB <20–22 mg/dL (term) or <18 mg/dL (preterm)

    If bilirubin levels do not stabilize (+/- 1 mg/dL) or decline, more intensive phototherapy may be warranted.

    Criteria for discontinuation of phototherapy

    Phototherapy may be discontinued when the criteria below are met:

    Discontinue phototherapy in healthy term infants: Continued phototherapy is not medically necessary when discontinuation criteria in the policy tables are met; routine delay in discharge solely to observe rebound bilirubin is not medically necessary and in most cases no further bilirubin measurement is required after stopping phototherapy.See Table 3

    Preterm Infants

    Preterm infants require modified phototherapy initiation and monitoring:

    Preterm phototherapy initiation: Manage physiologic hyperbilirubinemia in preterm infants (born <37 weeks gestation) per AAP guidelines; initiate phototherapy at 50–70% of the maximum indirect bilirubin levels specified in policy tables.50–70% of maximum indirect levels

    Preterm defined as <37 weeks gestation; consider complications (e.g., asphyxia, hypoxia, hemolysis) when assessing risk.

    Clofibrate

    Evidence summary and coverage context for clofibrate as an adjunct to phototherapy:

    Clofibrate evidence summary: Cochrane and randomized trial data (15 studies, including term and 2 preterm trials) reported lower TSB and shorter phototherapy duration when clofibrate was added to phototherapy in some populations; however, most trials were from a single region and studies did not report encephalopathy or mortality outcomes. Evidence is insufficient to recommend routine clinical use and clofibrate combined with phototherapy is considered experimental/investigational in this policy.

    Larger, geographically diverse trials with safety and long-term outcomes are needed.

    Zinc supplementation

    Evidence summary and coverage position for oral zinc supplementation:

    Zinc evidence summary: Systematic reviews and RCTs provide inconsistent results: some trials reported shorter phototherapy duration but most found no reduction in incidence of hyperbilirubinemia or need for phototherapy. Overall evidence does not support routine use of oral zinc for prevention of neonatal hyperbilirubinemia and UpToDate does not list zinc as a management option.

    Trials were heterogeneous in dose (5–20 mg/day), duration, and populations; insufficient evidence for standard care.

    Probiotics / Prebiotics

    Evidence summary for enteral probiotics and prebiotics in prevention or treatment:

    Probiotics/Prebiotics evidence summary: Systematic reviews and meta-analyses of small RCTs report reductions in TSB at some time points, shorter phototherapy duration, and decreased hospitalization in selected studies; however, the overall evidence is low quality, heterogeneous, and insufficient to recommend routine use. Larger, well-designed RCTs are needed to confirm efficacy and safety.

    Some meta-analyses pooled 645–1,761 infants across trials; GRADE assessments indicate low-quality evidence.

    Massage therapy

    Evidence summary and policy position for massage therapy:

    Massage evidence summary: Several small randomized trials (mostly using Field massage) reported reduced bilirubin levels and increased stool frequency; trial limitations and heterogeneity mean current evidence is insufficient to recommend routine clinical use of massage therapy for neonatal hyperbilirubinemia.

    Limited data in preterm infants; further rigorous trials required.

    Transcutaneous bilirubin devices

    Guidance on transcutaneous bilirubin (TcB) device use and limitations during/after phototherapy:

    TcB performance: Studies and systematic reviews demonstrate only moderate correlation between TcB and TSB during phototherapy (pooled r ≈ 0.65–0.72) and TcB often underestimates TSB; TcB measurements performed shortly after phototherapy are unreliable. When treatment decisions are being considered for infants exposed to phototherapy, TSB measurement is required rather than relying on TcB alone.

    UpToDate also states TcB is not reliable in infants undergoing phototherapy.

    Exchange transfusion and phototherapy indications

    Covered clinical actions and indications summarized from evidence:

    Exchange transfusion initiation: Initiate exchange transfusion for infants with very high bilirubin levels (e.g., bilirubin >25 mg/dL), infants not responding to phototherapy, or those with evidence of acute bilirubin encephalopathy; exchange transfusion should be performed in a neonatal intensive care unit (NICU) due to significant risks.bilirubin >25 mg/dL

    Initiation thresholds should be applied in the context of infant age in hours and neurotoxicity risk factors per AAP guidance.

    Adjunctive therapies (prebiotics/probiotics, clofibrate, metalloporphyrins, UDCA)

    Evidence summaries for adjunctive therapies evaluated as supplements to phototherapy:

    Prebiotics/probiotics: Limited, low-quality evidence from small trials suggests prebiotics or probiotics may reduce phototherapy duration or risk of hyperbilirubinemia in some studies, but current data are insufficient to recommend routine use; larger RCTs are required.small trials; low-quality evidence

    Cochrane and systematic reviews summarized.

    Clofibrate and metalloporphyrins added to phototherapy decreased bilirubin levels and phototherapy duration in trials, but safety data and long-term outcome information are inadequate; routine clinical use is not recommended and these agents are considered experimental/investigational in this policy.insufficient safety data

    Cochrane reviews and evidence-based reviews cited.

    Ursodeoxycholic acid (UDCA): Some small RCTs and meta-analyses report faster lowering of TSB and shorter phototherapy duration with UDCA as an adjunct, but study populations often excluded preterm neonates or those with hemolysis and overall evidence quality and neonatal safety data are limited; further high-quality studies are needed before routine use.low-to-moderate quality evidence

    Most UDCA studies excluded preterm neonates and those with significant hemolysis.

    Home-based and intermittent phototherapy

    Evidence summary for alternative phototherapy delivery methods:

    Home-based phototherapy: Meta-analysis of selected studies (n=259 neonates pooled) suggests home-based phototherapy can be effective and feasible compared with hospital-based phototherapy in selected infants, but overall evidence is limited and selection criteria should be applied.259 neonates pooled

    Home-based phototherapy requires appropriate eligibility and follow-up arrangements per policy.

    Intermittent versus continuous phototherapy: Systematic review and meta-analysis (n=716 neonates pooled) found intermittent phototherapy appears as effective as continuous phototherapy for reducing TSB, with fewer side effects and shorter phototherapy duration in some studies; some authors recommend intermittent phototherapy as preferred.716 neonates pooled

    Selection of intermittent versus continuous phototherapy should follow clinical judgment and available devices.

    The policy identifies a set of interventions that are considered experimental/investigational and not covered because their effectiveness for neonatal hyperbilirubinemia has not been established. Examples listed include measurement of end-tidal carbon monoxide corrected for ambient CO (ETCOc), genotyping of BLVRA, SLCO1B1, and UGT1A1 for risk assessment, transcutaneous bilirubin (TcB) devices used while the infant is undergoing phototherapy, metalloporphyrins (e.g., tin mesoporphyrin), antenatal phenobarbital for isoimmunized pregnancies, zinc supplementation, massage therapy, prebiotics/probiotics, and ursodeoxycholic acid (UDCA) as an adjuvant to phototherapy.

    Multiple systematic reviews and randomized trials of oral zinc (various doses and formulations) have not demonstrated a consistent reduction in the incidence of neonatal hyperbilirubinemia or need for phototherapy. Although some trials reported a shortened duration of phototherapy, pooled reviews concluded the evidence is limited, heterogeneous, and does not support routine use. An UpToDate treatment review also does not list zinc as a management option. Accordingly, routine oral zinc supplementation is not supported and is considered investigational for prevention of neonatal hyperbilirubinemia.

    Systematic reviews of ursodeoxycholic acid (UDCA) as an adjunct to phototherapy report methodological limitations and important population exclusions. Notably, the primary studies largely excluded preterm neonates and neonates with significant hemolysis, and were conducted in limited geographic areas; pharmacokinetic and safety data in newborns are sparse. Therefore, the results from these trials cannot be generalized to preterm or hemolytic neonates, limiting applicability of UDCA in those populations.

    This Clinical Policy Bulletin is provided as a general description to assist in administering plan benefits and clinical decision-making. It does not constitute a contract, guarantee coverage, or provide medical advice. Providers remain responsible for treatment decisions and should consult plan-specific coverage and prior authorization resources as appropriate.

    Inpatient phototherapy or admission is typically reserved for infants who meet age- and risk-adjusted bilirubin thresholds. Per the policy, inpatient treatment may be considered medically necessary for healthy full-term infants with TSB ≥20 mg/dL in the first postnatal week, and may be medically necessary for preterm infants with TSB ≥18 mg/dL. Conversely, inpatient care is generally not medically necessary for healthy full-term infants with TSB <20 mg/dL or for preterm infants with TSB <18 mg/dL, as many of these infants can be managed with expectant observation or home phototherapy when other criteria are met.

    Across systematic reviews and RCTs, available evidence does not support routine use of zinc supplementation to prevent neonatal jaundice. While isolated studies reported shorter phototherapy duration, overall results were inconsistent and meta-analyses did not show reductions in TSB at key time points or in incidence of hyperbilirubinemia. Therefore, zinc should not be used routinely as a preventive therapy for neonatal hyperbilirubinemia.

    Systematic reviews of probiotics and prebiotics report some small trials showing reduced total serum bilirubin, shorter phototherapy duration, or decreased hospitalization, but the evidence is limited and of low quality. Current reviews conclude that these data are insufficient to recommend routine probiotic or prebiotic use for prevention or treatment of neonatal jaundice; larger, well‑designed randomized trials are needed before routine adoption.

    Procedure, Drug and Diagnosis Codes

    Covered CPT CodesCPTCovered
    36450Exchange transfusion, blood; newborn
    82247Bilirubin; total
    82248Bilirubin; direct
    CPT codes listed (some not covered depending on indication)CPT
    81328SLCO1B1 gene analysis
    81350UGT1A1 gene analysis
    81400Molecular pathology procedure, Level 1
    97124Therapeutic massage
    Related genetic CPT CodesCPT
    81247G6PD gene analysis
    81248G6PD gene analysis
    81249G6PD gene analysis
    Infusion CPT CodesCPT
    96365Intravenous infusion
    96366Intravenous infusion (subsequent)
    96367IV infusion (additional)
    96368IV infusion (other)
    Covered HCPCS CodesHCPCSCovered
    E0202Phototherapy (bilirubin) light with photometer
    S9098Home visit, phototherapy services (e.g., Bili-lite), including equipment rental, nursing services, blood draw, supplies, and other services, per diem
    Drug HCPCSHCPCS
    J2560Injection, phenobarbital sodium, up to 120 mg
    J2561Injection, phenobarbital sodium, 1 mg
    Covered ICD-10 CodesICD-10Covered
    P55.0 - P55.9Hemolytic disease of newborn
    P57.0 - P57.9Kernicterus
    P58.0 - P58.9Neonatal jaundice due to other excessive hemolysis
    P59.0 - P59.9Neonatal jaundice from other and unspecified causes
    ICD-10 Codes Not Covered for Specific IndicationsICD-10Not Covered
    O36.111+ - O36.199+Maternal care for other isoimmunization [not covered for the use of antenatal phenobarbital in red cell isoimmunized pregnant women]
    Z15.89Genetic susceptibility to other disease [G6PD deficiency]
    Z83.49Family history of other endocrine, nutritional and metabolic diseases [G6PD deficiency]
    Z84.81Family history of carrier of genetic disease [G6PD deficiency]
    TSB thresholds for phototherapy and exchange transfusion
    Phototherapy thresholdsAge-in-hours specific TSB thresholds are provided in Table 1 (phototherapy) and are stratified by gestational age and presence/absence of risk factors (isoimmune hemolytic disease, G6PD deficiency, asphyxia, significant lethargy, temperature instability, sepsis, acidosis, or albumin <3.0 g/dL).
    Exchange transfusion thresholdsAge-in-hours specific TSB thresholds for exchange transfusion are provided in Table 2 and stratified by gestational age and risk-factor status (same risk-factor list as phototherapy).
    Prophylactic phototherapy indicationProphylactic phototherapy is considered medically necessary for infants with a rapid rise in bilirubin (>1 mg/dL/hour) and as a temporary measure when exchange transfusion is being contemplated.
    Inpatient treatment thresholdsInpatient treatment may be considered medically necessary for full-term infants with TSB ≥20 mg/dL in the first post-natal week; generally not necessary for full-term infants with TSB <20 mg/dL or preterm infants with TSB <18 mg/dL.
    Home phototherapy TSB thresholds
    Eligibility gestational ageInfant must have gestational age ≥35 weeks to qualify for home phototherapy.
    Term infant TSB requirementTotal serum bilirubin (TSB) must be less than 20 to 22 mg/dL for term infants for home phototherapy eligibility.
    Preterm infant TSB requirementTSB must be less than 18 mg/dL in preterm infants for home phototherapy eligibility.
    Follow-up requirementArrangements must be made for evaluation within 48 hours by clinic visit or home health nurse capable of clinical assessment and blood draws.

    Provider Requirements, Prior Authorization and Operational Guidance

    Documentation Required

    Reference the Clinical Policy Bulletin

    Providers should reference the Clinical Policy Bulletin (CPB) for neonatal hyperbilirubinemia (Aetna Clinical Policy 0332) when submitting claims or requesting services to ensure interventions (e.g., phototherapy, exchange transfusion, G6PD testing) meet documented medical necessity criteria and coding guidance.

    • Reference CPB 0332 when documenting indications, TSB thresholds, risk factors, and follow-up plans
    • Include relevant TSB values, age-in-hours, gestational age, and presence/absence of AAP risk factors in documentation
    Step Therapy

    Step therapy — Phototherapy first-line

    Step therapy: phototherapy is the first-line treatment for term and near-term infants per AAP guidance and this CPB. Pharmacologic or adjuvant therapies (e.g., clofibrate, zinc, ursodeoxycholic acid, metalloporphyrins) are considered investigational or have limited evidence and should not replace initial phototherapy. Exchange transfusion is reserved for infants meeting age-in-hours specific thresholds or who fail to respond to intensive phototherapy.

    • Initiate phototherapy according to age-in-hours TSB thresholds and risk-factor stratification
    • Do not use zinc or other adjuvant agents as a substitute for standard phototherapy; document rationale if used as adjunct
    • Reserve exchange transfusion for TSB above exchange thresholds or non-response to intensive phototherapy — perform in NICU setting

    Clinical Background and Evidence Summary

    This policy adapts American Academy of Pediatrics guidance for neonatal hyperbilirubinemia. It summarizes phototherapy initiation and exchange transfusion thresholds using age-in-hours specific TSB tables adjusted for gestational age and presence of risk factors (isoimmune hemolytic disease, G6PD deficiency, asphyxia, significant lethargy, temperature instability, sepsis, acidosis, or albumin <3.0 g/dL). Phototherapy is the primary recommended therapy and exchange transfusion is reserved for infants exceeding age/TSB thresholds or those with evidence of acute bilirubin encephalopathy.

    Definitions and Risk Factors

    Clinical risk factors
    Isoimmune hemolytic diseaseListed as a neurotoxicity risk factor that increases bilirubin management risk and affects threshold stratification.
    G6PD deficiencyIdentified as a risk factor for severe hyperbilirubinemia and included in risk-factor stratification for thresholds.
    Perinatal asphyxia and significant lethargyAsphyxia and significant lethargy are included among clinical risk factors influencing management thresholds.
    Temperature instability, sepsis, acidosisTemperature instability, sepsis, and acidosis are enumerated clinical risk factors that raise neurotoxicity risk and alter thresholds.
    Low albuminAlbumin <3.0 g/dL (if measured) is noted as a risk factor affecting TSB threshold stratification.
    Preterm infant
    DefinitionPreterm infant defined as an infant born prior to 37 weeks gestation.
    Phototherapy initiation guidanceIn preterm infants, phototherapy should be initiated at 50–70% of the maximum indirect bilirubin levels specified in the policy tables (Table 4).
    Complication examplesComplications that increase concern include prenatal asphyxia, acidosis, hypoxia, hypoalbuminemia, meningitis, intraventricular hemorrhage, hemolysis, hypoglycemia, or signs of kernicterus.
    Genetic risk factors
    Genes implicatedPolymorphisms in G6PD, UGT1A1, and SLCO1B1 can influence bilirubin production and metabolism and modulate hyperbilirubinemia risk.
    SLCO1B1 variantsSLCO1B1 388 G>A has been associated with increased neonatal hyperbilirubinemia risk in some populations (e.g., Chinese neonates) but associations vary by ethnicity.
    UGT1A1 (Gilbert) allelesUGT1A1*28 (Gilbert syndrome) association with neonatal extreme hyperbilirubinemia is uncertain; studies have not consistently shown an association.
    Exchange transfusion
    DefinitionExchange transfusion is a procedure replacing the infant's blood volume twice with donor red cells to remove bilirubin and antibodies causing hemolysis.
    IndicationsIndicated for very high bilirubin levels (e.g., bilirubin >25 mg/dL), failure to respond to phototherapy, or evidence of acute bilirubin encephalopathy.
    Setting requirementExchange transfusion should be performed in a neonatal intensive care unit (NICU) due to significant risks.
    G6PD testing
    DefinitionG6PD testing measures glucose-6-phosphate dehydrogenase level in jaundiced infants.
    Recommended use casesMeasure G6PD level for jaundiced infants receiving phototherapy when family history or ethnic/geographic origin suggests G6PD deficiency, or when response to phototherapy is poor.
    Guideline sourceRecommendation aligns with American Academy of Pediatrics guidance cited in the policy.
    Clinical Policy Bulletin
    PurposeClinical Policy Bulletins are documents developed to assist Aetna in administering plan benefits and to provide guidance on policy application.
    Not a guaranteeThe bulletin is informational and does not constitute an offer of coverage, a contract, or medical advice; it may be updated and does not guarantee benefits.
    Provider responsibilityProviders remain responsible for treatment decisions and should reference the bulletin and review history when submitting documentation for coverage determinations.

    Policy Dates and Revision History

    2023-08-10Last reviewLatest

    Policy last reviewed on 08/10/2023.

    1999-05-25Effective date

    Policy originally became effective on 05/25/1999.

    2024-03-28Next scheduled review

    Next policy review scheduled for 03/28/2024.